4.6 Article

SGLT2 Inhibitor Induced Sympathoinhibition A Novel Mechanism for Cardiorenal Protection

期刊

JACC-BASIC TO TRANSLATIONAL SCIENCE
卷 5, 期 2, 页码 169-179

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacbts.2019.11.007

关键词

denervation; heart; hypertension; kidney; SGLT2; sympathetic nervous system

资金

  1. Royal Perth Hospital Research Foundation
  2. Diabetes Research Western Australia
  3. National Health and Medical Research Council
  4. Boehringer Ingelheim
  5. Medtronic
  6. Abbott
  7. Novartis
  8. Servier
  9. Pfizer

向作者/读者索取更多资源

Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic hypertensive Schlager (BPH/2J) mice reduced blood pressure, improved glucose homeostasis, and reduced renal SGLT2 protein expression. Inhibition of SGLT2 prevented weight gain, reduced blood pressure, significantly reduced elevations of tyrosine hydroxytase and norepinephrine, and protects against endothelial dysfunction. These findings provide evidence for significant crosstalk between activation of the sympathetic nervous system and SGLT2 regulation and possible ancillary effects on endothelial function, which may contribute to the observed cardiorenal protective effects of SGLT2 inhibition. (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据